- About Us
- Our Programs
- Our Events
- uCity Square
- Support Us
January 8, 2018 | NASDAQ
Mid-Atlantic Bio Angels (MABA) announces today that Group K Diagnostics (Group K), a Philadelphia-based diagnostics company developing a multi-test modular point of care diagnostic platform, was named “Best of the Best” at MABA's 1st Pitch Life Science event held on December 13, 2017 at the Alexandria Center in New York.
“We are gratified to have been chosen among such an impressive field of companies to be the ‘Best of the Best’ at 1st Pitch this year,” said Brianna Wronko, CEO of Group K Diagnostics. “We believe our rapid, cost-effective diagnostics will present a true advantage in the market and to patient care, and we appreciate the support we’ve received from MABA in terms of feedback and attention as we continue to develop our platform.”
Group K is developing a low-cost, point-of-care diagnostic system using paper-based microfluidics to provide multiple results from one patient sample within 20 minutes or less. Initially offering a diagnostic for liver function, the device is read with a smartphone app. Twelve more tests are in production, with over 60 in the pipeline. The company hopes the device will solve healthcare practitioners’ need for a versatile, rapid and cost-effective point-of-care diagnostic device.
“Over the course of this year, we saw a variety of strong companies at our 1st Pitch events. Six 2017 “Best in Show” winners, packing new and improved pitches, came to the Alexandria Center to compete for the title of “Best of the Best”. We are pleased that the audience selected Group K, which delivered an excellent presentation, as ‘Best of the Best,’” said Yaniv Sneor, a MABA co-founder and president of Blue Cactus Consulting. “We look forward to seeing Group K continue its development and bring its technology to market.”
About 1st Pitch Life Science
At a 1stPitch event (http://www.1stpitchlifescience.com), early stage life sciences and healthcare companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 15-minute audience Q&A. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1st Pitch are invited to hear the panel constructively critique the company's presentation, business model and perceived viability in the market.
Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA's goal is to create an environment where the depth of investors' knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.